Patents by Assignee Ethypharm
  • Publication number: 20080031946
    Abstract: The invention relates to low-dose tablets obtained by directly compressing microgranules essentially constituted of a neutral support covered by a polymeric layer containing at least one pharmaceutically acceptable polymer and permitting the modified release of active substances in an aqueous medium, to which an active layer containing at least one active substance is applied. The inventive tablets advantageously exhibit a matrix effect similar to that obtained with conventional matrix tablets that depends on the nature of the polymer(s) used for the constitution of the polymeric layer. This matrix effect makes it possible to modify the release profile of the transported active substance based on the type of the polymer used. These tablets are particularly suited for realizing low-dose tablets. The invention also relates to a method for producing these tablets and to the use thereof, particularly for administering active substances in low to very low doses.
    Type: Application
    Filed: November 10, 2004
    Publication date: February 7, 2008
    Applicant: ETHYPHARM
    Inventors: Pierre Tchoreloff, Bernard Leclerc, Guillaume Benoist, Laurent Bertocchi
  • Publication number: 20070141158
    Abstract: The invention relates to an amphiphilic heparin derivative formed from at least one type of partially N-desulfated heparin and at least one type of bile acid comprising one or several bile acid molecules grafted on a heparin molecule by an amide bond formed between the terminal carboxylic acid function of a bile acid and a primary heparin amine function which is initially present in the heparin or resulting from the N-desulfation. The inventive derivative is characterized in that the number of grafted bile acid molecules per 100 heparin disaccharide units ranges from 15 to 80 approximately.
    Type: Application
    Filed: December 17, 2004
    Publication date: June 21, 2007
    Applicant: ETHYPHARM
    Inventors: Didier Hoarau, Mahfoud Boustta, Christian Braud, Michel Vert
  • Publication number: 20070071812
    Abstract: The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables to enhance the bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent.
    Type: Application
    Filed: August 25, 2006
    Publication date: March 29, 2007
    Applicant: LABORATOIRES DES PRODUITS ETHIQUES ETHYPHARM
    Inventors: Bruno Criere, Pascal Suplie, Philippe Chenevier
  • Publication number: 20070036861
    Abstract: The present invention relates to a multilayer orodispersible tablet and to the process for preparing it.
    Type: Application
    Filed: June 4, 2004
    Publication date: February 15, 2007
    Applicant: ETHYPHARM
    Inventors: Pascal Oury, Gael Lamoureux, Catherine Herry, Yann Prevost
  • Patent number: 7101574
    Abstract: The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables enhanced bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent.
    Type: Grant
    Filed: July 7, 2000
    Date of Patent: September 5, 2006
    Assignee: Laboratoires des Produits Ethiques Ethypharm
    Inventors: Bruno Criere, Pascal Suplie, Philippe Chenevier
  • Publication number: 20060182836
    Abstract: The invention relates to an improved extruder for the production of spheroidal or spheroid particles. The inventive extruder consists of a cutting tool comprising knives which take the form of a rectangular blade having first and second flat parallel faces. The aforementioned blade takes the form of a knife owing to a recess which is provided on one of the faces thereof. The recess is only provided on one part of the face in question, such that one of the long sides of said face comprises a narrow flange. Moreover, the two faces of the blade are connected by an inclined surface which extends between the non-recessed face and the narrow flange, the edge of which is used to cut the extruded profile. The extruder also comprises an extrusion die consisting of a ring piece and a cylindrical cap having an axis.
    Type: Application
    Filed: February 9, 2004
    Publication date: August 17, 2006
    Applicant: Ethypharm
    Inventors: Alexandre Gil, Marc Ouattara, Laurent Bertocchi
  • Publication number: 20060177508
    Abstract: The invention concerns an improved multiparticulate tablet disintegrating in the mouth in contact with saliva in less than 40 seconds. The invention is characterised in that it is based on particles of coated active principle, said particles having intrinsic compression properties and a mixture of carriers, the proportion of carrier mixture relative to coated active principle particles being 0.4 to 6 parts by weight, the carrier mixture comprising: a disintegrating agent; a diluting soluble agent with binding properties; a lubricant; a permeabilizing agent; and advantageously lubricants, sweeteners, flavouring and colouring agents, the proportion of disintegrating agent and soluble agent relative to the tablet mass being 1 to 15 wt. % for the former and 30 to 90 wt. % for the latter.
    Type: Application
    Filed: March 6, 2006
    Publication date: August 10, 2006
    Applicant: Ethypharm
    Inventors: Charles Chauveau, Jean-Marc Zuccarelli, Nourredine Nouri, Maryvonne Barbero
  • Publication number: 20060165794
    Abstract: The invention relates to a directly-compressible gastro-resistant spheroid. The spheroid comprises: (i) a core containing one or more active substances; (ii) a flexible, deformable film which directly coats the aforementioned core and which comprises an enteric polymer and a mixture of saturated and/or unsaturated polyglycosylated glycerides, the fatty acids of which include at least 8 carbon atoms; and (iii) an outer water-dispersible layer containing at least one disintegrating agent.
    Type: Application
    Filed: October 3, 2003
    Publication date: July 27, 2006
    Applicant: Ethypharm
    Inventors: Philippe Chenevier, Dominique Marechal
  • Patent number: 7067149
    Abstract: The invention concerns an improved multiparticulate tablet disintegrating in the mouth in contact with saliva in less than 40 seconds. The invention is characterized in that it is based on particles of coated active principle, said particles having intrinsic compression properties and a mixture of carriers, the proportion of carrier mixture relative to coated active principle particles being 0.4 to 6 parts by weight, the carrier mixture comprising: a disintegrating agent; a diluting soluble agent with binding properties; a lubricant; a permeabilizing agent; and advantageously lubricants, sweeteners, flavoring and coloring agents, the proportion of disintegrating agent and soluble agent relative to the tablet mass being 1 to 15% by weight for the former and 30 to 90% by weight for the latter.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: June 27, 2006
    Assignee: Ethypharm
    Inventors: Charles Chauveau, Jean-Marc Zuccarelli, Nourredine Nouri, Maryvonne Barbero
  • Publication number: 20060134422
    Abstract: Active principle-based coated particle, in which both the core and the coating contain active principle, includes a core which contains a first active principle while the coating contains a second active principle, which is different in nature.
    Type: Application
    Filed: January 21, 2004
    Publication date: June 22, 2006
    Applicant: Ethypharm
    Inventors: Philippe Chenevier, Dominique Marechal
  • Patent number: 7063864
    Abstract: The present invention concerns a novel sustained-release oral formulation of morphine sulphate in the form of microgranules. Each microgranule comprises a neutral support grain coated with an active layer and with a sustained-release layer, characterized in that the sustained-release layer contains a copolymer of methacrylic acid and of methyl methacrylate ester, the relative proportion of the free carboxyl groups and of the ester groups of which is equal to 0.5 approximately, and a silica exhibiting a hydrophobic character. The present invention also concerns a process for preparing these microgranules which is carried out entirely in aqueous medium by emplacing on neutral support grains.
    Type: Grant
    Filed: June 8, 2000
    Date of Patent: June 20, 2006
    Assignee: Laboratoires des Products Ethiques Ethypharm
    Inventors: Dominique Marechal, Pascal Suplie, Pascal Oury
  • Publication number: 20060121115
    Abstract: The invention relates to a heat-sensitive composition in liquid form, containing: an organic hydrophobic liquid; an organogelling substance, the molecules of which can be bound to one another by low energy linkages; and a bioactive substance, which switches to organogel form upon coming into contact with a physiological fluid during the administration thereof into an animal body, in particular, a human.
    Type: Application
    Filed: March 12, 2003
    Publication date: June 8, 2006
    Applicants: Ethypharm, Universite De Montreal
    Inventors: Jean-Christophe Leroux, Anne-Claude Couffin-Hoarau
  • Patent number: 7041241
    Abstract: The invention relates to the use of biodegradable microspheres that release a radiosensitizing anticancer agent for producing a medicament to be used simultaneously with, separately from or spread over time with a radiotherapy, for treating glioblastoma. The use of said biodegradable microspheres according to the invention results in a patient survival time of at least 90 weeks, a therapeutically effective concentration being maintained in the parenchymatous area throughout this time. The microspheres used preferably contain 5-fluorouracile of the tumor, by intratissular injection. The radiotherapy targeting the tumorous mass is dosed at 60 Gy over approximately 6 weeks. The invention also relates to a method for producing the biodegradable microspheres by emulsion-extraction, and to a suspension containing the biodegradable microspheres obtained using this method.
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: May 9, 2006
    Assignee: Laboratoires des Prodiuts Ethiques Ethypharm
    Inventors: Nathalie Faisant, Jean-Pierre Benoit, Philippe Menei
  • Patent number: 6967028
    Abstract: The present invention provides microspheres intended to be administered by injection comprising a protein active ingredient and an agent coating the active ingredient intended to prolong its release, wherein they are free of any trace of organic solvent and they can be obtained according to a coating method involving bringing the active ingredient and the coating agent into contact, with stirring, in a supercritical fluid, said coating agent being soluble in this supercritical fluid.
    Type: Grant
    Filed: June 5, 2001
    Date of Patent: November 22, 2005
    Assignees: Mainelab, Laboratoires des Produits Ethiques Ethypharm
    Inventors: Claire Dulieu, Joël Richard, Jean-Pierre Benoit
  • Patent number: 6951657
    Abstract: The invention concerns coated particles based on granulated microcrystals of ibuprofen, its pharmaceutically acceptable isomers and salts, characterized in that they comprise a coating obtained in a fluidized bed apparatus with a hydroalcoholic dispersion consisting of a mixture comprising (A) 5 to 50% by weight of ethylcellulose relative to ibuprofen; (B) 10 to 60% by weight of hydroxypeopylmethylcellulose relative to the ethylcellulose; and (C) 1 to 40% by weight of silica with antistatic and permeabilizing properties relative to the ethylcellulose, the resulting coating, whereof at least one of the constituents can be used for granulating the ibuprofen microcrystals resulting in said particles, thereby masking the unpleasant taste of ibuprofen and significantly reducing its irritating effect on the throat after deglutition and substantially immediate release of ibuprofen when the particles are placed in an aqueous medium.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: October 4, 2005
    Assignee: Laboratoires des produits Ethiques Ethypharm SA
    Inventors: Jean-Marc Zuccarelli, Charles André Chauveau, Gilles DeMichelis, Karine Jean
  • Publication number: 20050214378
    Abstract: The present invention relates to stealth lipid nanocapsules comprising an essentially lipid core which is liquid or semi-liquid at ambient temperature, and an outer lipid envelope comprising at least one hydrophilic surfactant which is lipidic in nature, at least one lipophilic surfactant which is lipidic in nature and at least one amphiphilic derivative of poly(ethylene glycol), the molar mass of the poly(ethylene glycol) component of which is greater than or equal to 1000 g/mol, preferably greater than or equal to 2000 g/mol, to the methods for the preparation thereof and to the use thereof as a carrier for active principle(s).
    Type: Application
    Filed: June 11, 2003
    Publication date: September 29, 2005
    Applicant: ETHYPHARM
    Inventors: Didier Hoarau, Pascal Delmas, Jean-Christophe Delmas
  • Publication number: 20050152976
    Abstract: The invention concerns coated particles with prolonged release, a method for preparing same and multiparticulate tablets comprising said coated particles.
    Type: Application
    Filed: April 23, 2003
    Publication date: July 14, 2005
    Applicant: ETHYPHARM
    Inventors: Phillippe Chenevier, Dominique Marechal
  • Patent number: 6803052
    Abstract: The invention relates to the use of biodegradable microspheres that release a radiosensitizing anticancer agent for producing a medicament to be used simultaneously with, separately from or spread over time with a radiotherapy, for treating glioblastoma. The use of said biodegradable microspheres according to the invention results in a patient survival time of least 90 weeks, a thereapeutically effective concentration being maintained in the parenchymatous area throughout this time. The microspheres used prefereably contain 5-fluorouracile of the tumor, by intratissular injection. The radiothereapy targeting the tumorous mass is dosed at 60 Gy over approximately 6 weeks. The invention also relates to a method for producing the biodegradable microspheres by emulsion-extraction, and to a suspension containing the biodegradable microspheres obtained using this method.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: October 12, 2004
    Assignee: Laboratoires des Produits Ethiques Ethypharm
    Inventors: Nathalie Faisant, Jean-Pierre Benoit, Philippe Menei
  • Patent number: 6794411
    Abstract: The invention relates to a drinkable ibuprofen solution wherein the soluble fraction of the active ingredient contained therein is less than 10% by weight in relation to the weight of the suspension.
    Type: Grant
    Filed: November 6, 2001
    Date of Patent: September 21, 2004
    Assignee: Laboratoire des Produits Ethiques Ethypharm
    Inventors: Christophe Lebon, Emmanuel Guerin, Pascal Suplie
  • Patent number: 6770298
    Abstract: The invention concerns a device for producing granules, in particular pharmaceutical granules, comprising a drum (4) with peripheral apertures (25) and a member (30) feeding the drum with coating or fixing substance. The drum (4) comprises mutually parallel sections (22) defining between them the apertures (25).
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: August 3, 2004
    Assignee: Laboratoires des Produits Ethiques Ethypharm
    Inventors: Patrice Debregeas, Gérard Leduc, Pascal Oury, Patrice Romain